NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis $6.00 -0.24 (-3.85%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$6.23 +0.23 (+3.83%) As of 07/3/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Scilex Stock (NASDAQ:SCLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Scilex alerts:Sign Up Key Stats Today's Range$6.00▼$6.3750-Day Range$4.01▼$6.9752-Week Range$3.60▼$73.50Volume26,329 shsAverage Volume67,610 shsMarket Capitalization$41.70 millionP/E RatioN/ADividend YieldN/APrice Target$455.00Consensus RatingModerate Buy Company Overview Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Read More Scilex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSCLX MarketRank™: Scilex scored higher than 31% of companies evaluated by MarketBeat, and ranked 715th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingScilex has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageScilex has only been the subject of 2 research reports in the past 90 days.Read more about Scilex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.57) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Scilex's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.73% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scilex has recently increased by 23.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.73% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scilex has recently increased by 23.40%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Scilex this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.94% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scilex's insider trading history. Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLX Stock News HeadlinesSCLX Scilex Holding Company - Seeking AlphaJuly 1, 2025 | seekingalpha.comScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...June 25, 2025 | theglobeandmail.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 6 at 2:00 AM | Brownstone Research (Ad)Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the BoardJune 23, 2025 | globenewswire.comScilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review JournalJune 5, 2025 | globenewswire.comScilex Holding Stock Price HistoryJune 1, 2025 | investing.comScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FLMay 16, 2025 | globenewswire.comScilex adjusts director compensation post-stock splitMay 13, 2025 | investing.comSee More Headlines SCLX Stock Analysis - Frequently Asked Questions How have SCLX shares performed this year? Scilex's stock was trading at $14.9240 at the beginning of the year. Since then, SCLX shares have decreased by 59.8% and is now trading at $6.00. How were Scilex's earnings last quarter? Scilex Holding Company (NASDAQ:SCLX) issued its earnings results on Friday, January, 17th. The company reported ($6.30) earnings per share for the quarter. When did Scilex's stock split? Scilex's stock reverse split on Tuesday, April 15th 2025.The 1-35 reverse split was announced on Friday, April 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Nikola (NKLA) and BlackBerry (BB). Company Calendar Last Earnings1/17/2025Today7/06/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCLX CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$455.00 High Stock Price Target$630.00 Low Stock Price Target$245.00 Potential Upside/Downside+7,483.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($29.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.81 million Net Margins-146.93% Pretax Margin-146.94% Return on EquityN/A Return on Assets-82.65% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.09 Sales & Book Value Annual Sales$56.59 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value($27.68) per share Price / Book-0.22Miscellaneous Outstanding Shares6,950,000Free Float6,400,000Market Cap$41.70 million OptionableOptionable Beta1.19 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:SCLX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.